View More Recent Stories
-
Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
-
Lucid Diagnostics Inc. (LUCD) Reports In-Line Q2 EPS
-
Lucid Diagnostics (LUCD) Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing
-
Lucid Diagnostics Inc (LUCD) Files for up to 72.36M Share Offering by Selling Stockholders
-
Lucid Diagnostics (LUCD) Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Popula
